Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lexaria Bioscience Corp. Director's Dealing 2024

May 10, 2024

34983_dirs_2024-05-10_ed22fa4d-b929-4c74-bce2-0ced691cc236.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2024-04-26

Reporting Person: Carle Vanessa (Secretary)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-04-26 Stock Options $2.36 A 10000 Acquired 2029-04-26 Common Shares (10000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
common shares 67 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Warrants $36 2024-11-13 Common Shares (67) 67 Direct
Stock Options $3 2026-04-26 Common Shares (12500) 12567 Direct
Stock Options $3 2026-06-08 Common Shares (5000) 17567 Direct
Stock Options $3 2026-09-01 Common Shares (10000) 27567 Direct
Stock Options $2.91 2027-08-29 Common Shares (12500) 40067 Direct
Stock Options $1.15 2028-10-26 Common Shares (12500) 52567 Direct

Footnotes

F1: Repriced from $5.31 pursuant to shareholder approval received May 9, 2023

F2: Repriced from $7.08 pursuant to shareholder approval received May 9, 2023

F3: Repriced from $6.23 pursuant to shareholder approval received May 9, 2023